Companies › LimmaTech Biologics
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Infectious disease; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Shigella4V2 Tetravalent bioconjugate vaccine | – | Phase 2 | Shigellosis | – |
| LTB-NG6 Multivalent Neisseria gonorrhoeae vaccine | – | Phase 1 | Neisseria Gonorrhea | Apr 2027 |
| Candi5V Pentavalent bioconjugate vaccine against Candida species | – | Phase 1 | Recurrent Vulvovaginal Candidiasis | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06615375 | Shigella4V2 | Phase 2 | Shigellosis | Infectious disease | Apr 2026 |
| NCT07758972 | LTB-NG6 | Phase 1 | Neisseria Gonorrhea | Infectious disease | Apr 2027 |
| NCT06190509 | Candi5V | Phase 1 | Recurrent Vulvovaginal Candidiasis | Infectious disease | Apr 2027 |
No annotated target.
–
Inventprise SK Bioscience Immorna Biotherapeutics Sinovac Life Sciences Bharat Biotech International
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.